Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Meclofenamate Sodium	Capsule	100 mg/1	Oral	Mylan Pharmaceuticals Inc.	1986-09-03	Not applicable
Meclofenamate Sodium	Capsule	50 mg/1	Oral	Mylan Pharmaceuticals Inc.	1986-09-03	Not applicable
Meclofenamate Sodium	Capsule	50 mg/1	Oral	Physicians Total Care, Inc.	1986-09-03	2002-06-30

Additional Data Available

Application Number

A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

Learn more

Product Code

A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

Learn more

International/Other Brands

Ethos (Yung Shin) / Eucome (U-Liang) / Meclomen (Pfizer)

Categories

UNII

48I5LU4ZWD

CAS number

644-62-2

Weight

Average: 296.149
Monoisotopic: 295.016684015

Chemical Formula

C₁₄H₁₁Cl₂NO₂

InChI Key

SBDNJUWAMKYJOX-UHFFFAOYSA-N

InChI

InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)

IUPAC Name

2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid

SMILES

CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1

Pharmacology

Indication

For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.

Associated Conditions

Pharmacodynamics

Meclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.

Mechanism of action

The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.

Target	Actions	Organism
AProstaglandin G/H synthase 1	inhibitor	Humans
AProstaglandin G/H synthase 2	inhibitor	Humans
AArachidonate 5-lipoxygenase	inhibitor	Humans
UPotassium voltage-gated channel subfamily KQT member 2	other	Humans
UPotassium voltage-gated channel subfamily KQT member 3	other	Humans

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (C_max) decreased fourfold and the time to C_max was delayed by 3 hours.

Volume of distribution

9.1 to 43.2 L

Protein binding

Greater than 99% bound to plasma proteins over a wide drug concentration range.

Metabolism

Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.

Route of elimination

Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.

Half life

In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.

Clearance

Oral cl=206 mL/min

Toxicity

After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
(R)-warfarin	The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with (R)-warfarin.
(S)-Warfarin	The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamine	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin	The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine	The risk or severity of hypertension can be increased when Meclofenamic acid is combined with 4-Methoxyamphetamine.
5-fluorouridine	The therapeutic efficacy of Meclofenamic acid can be decreased when used in combination with 5-fluorouridine.

Additional Data Available

Extended Description

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

References

Synthesis Reference

U.S. Patent 3,313,848.

General References

Not Available

External Links

Human Metabolome Database: HMDB0015074
KEGG Drug: D02341
KEGG Compound: C07117
PubChem Compound: 4037
PubChem Substance: 46507887
ChemSpider: 3897
BindingDB: 22971
ChEBI: 6710
ChEMBL: CHEMBL509
Therapeutic Targets Database: DNC000919
PharmGKB: PA450341
HET: JMS
RxList: RxList Drug Page
Wikipedia: Meclofenamic_acid

ATC Codes

M01AG04 — Meclofenamic acid

M02AA18 — Meclofenamic acid

PDB Entries

3r6i / 4n6p / 4qkn / 5ikq / 6ijx

MSDS

Download (74.2 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Bipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenia	1
Not Available	Active Not Recruiting	Treatment	Progressive Brain Metastases / Recurrent Brain Metastases	1

Pharmacoeconomics

Manufacturers

Quantum pharmics ltd
American therapeutics inc
Barr laboratories inc
Mylan pharmaceuticals inc
Par pharmaceutical inc
Sandoz inc
Usl pharma inc
Vitarine pharmaceuticals inc
Watson laboratories inc
Parke davis div warner lambert co

Packagers

Dispensing Solutions
Mylan
Nucare Pharmaceuticals Inc.
Pharmedix
Physicians Total Care Inc.
Sandhills Packaging Inc.

Dosage forms

Form	Route	Strength
Capsule	Oral	100 mg/1
Capsule	Oral	50 mg/1

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	248-250	U.S. Patent 3,313,848.
water solubility	30 mg/L	MERCK INDEX (1996)
logP	5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00366 mg/mL	ALOGPS
logP	5.11	ALOGPS
logP	6.09	ChemAxon
logS	-4.9	ALOGPS
pKa (Strongest Acidic)	3.79	ChemAxon
pKa (Strongest Basic)	-3.6	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	49.33 Å²	ChemAxon
Rotatable Bond Count	3	ChemAxon
Refractivity	76.45 m³·mol^-1	ChemAxon
Polarizability	28.44 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9393
Blood Brain Barrier	+	0.8668
Caco-2 permeable	+	0.8398
P-glycoprotein substrate	Non-substrate	0.806
P-glycoprotein inhibitor I	Non-inhibitor	0.8943
P-glycoprotein inhibitor II	Non-inhibitor	0.9474
Renal organic cation transporter	Non-inhibitor	0.9094
CYP450 2C9 substrate	Non-substrate	0.6402
CYP450 2D6 substrate	Non-substrate	0.9164
CYP450 3A4 substrate	Non-substrate	0.6566
CYP450 1A2 substrate	Inhibitor	0.9236
CYP450 2C9 inhibitor	Inhibitor	0.9106
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.8271
CYP450 3A4 inhibitor	Non-inhibitor	0.8308
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.558
Ames test	Non AMES toxic	0.8633
Carcinogenicity	Non-carcinogens	0.5329
Biodegradation	Not ready biodegradable	0.9709
Rat acute toxicity	3.0345 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9502
hERG inhibition (predictor II)	Non-inhibitor	0.872

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0006-0090000000-dc6d0aaa7ee199899830
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-052f-0090000000-4f2a28033e59bab0257a
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-03di-0190000000-b6abcaff657bfa67b599
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-03fr-0690000000-eccbe792d08156c89c39
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-004i-0920000000-fdcf8eff9ac77cf86d5b
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-004i-0900000000-77140947d50a131a9be6
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-004i-0900000000-5d2a4942eea2a2d2f252
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-004i-0090000000-85032b374ac40bac481a
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-004l-0090000000-a2cbafbde1150bf5812e
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0006-0090000000-47d80abc4f95a2c5ef4c
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0006-0090000000-cfa40a800c6a52f6a264
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0006-0290000000-2e34cb2892f6263b39fa
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0563-0980000000-54fb4017b6a67acb639b
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-004i-0910000000-26fefd3e49fc0ba3e36e
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0fb9-1900000000-448908b1e79c92a656d7
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0fb9-2900000000-71b13766bf05541800b4

Taxonomy

Description: This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Benzoic acids and derivatives
Direct Parent: Aminobenzoic acids
Alternative Parents: Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Dichlorobenzenes / Benzoyl derivatives / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives
show 6 more
Substituents: Aminobenzoic acid / Benzoic acid / Benzoyl / 1,3-dichlorobenzene / Aniline or substituted anilines / Aminotoluene / Toluene / Chlorobenzene / Halobenzene / Aryl chloride
show 19 more
Molecular Framework: Aromatic homomonocyclic compounds
External Descriptors: organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:6710)

Targets

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	220	N/A	N/A	23454516

Details1. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name: PTGS1
Uniprot ID: P23219
Uniprot Name: Prostaglandin G/H synthase 1
Molecular Weight: 68685.82 Da

References

Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961]
Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641]
Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631]

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	40	N/A	N/A	11844663
IC 50 (nM)	50	8	37	10639181
IC 50 (nM)	700	N/A	N/A	23454516
Ki (nM)	200	N/A	N/A	10377455
Ki (nM)	700	N/A	N/A	10377455

Details2. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name: PTGS2
Uniprot ID: P35354
Uniprot Name: Prostaglandin G/H synthase 2
Molecular Weight: 68995.625 Da

References

Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963]
Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292]
Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862]

Details3. Arachidonate 5-lipoxygenase

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Iron ion binding
Specific Function: Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name: ALOX5
Uniprot ID: P09917
Uniprot Name: Arachidonate 5-lipoxygenase
Molecular Weight: 77982.595 Da

References

Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679]
Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588]

Details4. Potassium voltage-gated channel subfamily KQT member 2

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Other

General Function: Voltage-gated potassium channel activity
Specific Function: Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current...
Gene Name: KCNQ2
Uniprot ID: O43526
Uniprot Name: Potassium voltage-gated channel subfamily KQT member 2
Molecular Weight: 95846.575 Da

References

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]

Details5. Potassium voltage-gated channel subfamily KQT member 3

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Other

General Function: Voltage-gated potassium channel activity
Specific Function: Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native ...
Gene Name: KCNQ3
Uniprot ID: O43525
Uniprot Name: Potassium voltage-gated channel subfamily KQT member 3
Molecular Weight: 96741.515 Da

References

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]

Carriers

Details1. Thyroxine-binding globulin

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Substrate

General Function: Serine-type endopeptidase inhibitor activity
Specific Function: Major thyroid hormone transport protein in serum.
Gene Name: SERPINA7
Uniprot ID: P05543
Uniprot Name: Thyroxine-binding globulin
Molecular Weight: 46324.12 Da

References

CYTOMEL (liothyronine) FDA label [File]

Transporters

Details1. Solute carrier family 22 member 6

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Sodium-independent organic anion transmembrane transporter activity
Specific Function: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name: SLC22A6
Uniprot ID: Q4U2R8
Uniprot Name: Solute carrier family 22 member 6
Molecular Weight: 61815.78 Da

References

Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]

Details2. Solute carrier organic anion transporter family member 1C1

Kind: Protein
Organism: Humans
Pharmacological action: Unknown
Actions: Inhibitor

General Function: Thyroid hormone transmembrane transporter activity
Specific Function: Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
Gene Name: SLCO1C1
Uniprot ID: Q9NYB5
Uniprot Name: Solute carrier organic anion transporter family member 1C1
Molecular Weight: 78695.625 Da

References

Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on January 02, 2020 04:41

Meclofenamic acid

Identification

Structure for Meclofenamic acid (DB00939)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

References

References

Carriers

References

Transporters

References

References